InvestorsHub Logo
icon url

dukesking

07/26/19 10:01 AM

#203935 RE: hayward #203929

Hayward, I’m with you. The label expansion will bring many new investors and possibly a buyout offer. Even without an offer, a broad and favorable label will bring the price up several dollars. The only reason we’re not in the 20’s now is the hangover felt from the dilution. We may see $20 plus organically from Q2 earnings report and JPM/GS price target estimates coming out and more insurance companies changing coverages in front of label expansion. Many possible drivers of the stock price ahead of label. IMO.
icon url

amarinbullfromchicago

07/26/19 10:52 AM

#203951 RE: hayward #203929

Not negative at all, just the opposite. But you kind of contradicted yourself, no? I agree approval is obvious and a shoe in, so why would we shoot up after? I think most people have us priced in for approval, so the real buying/surprising the street will not be because we get approved, but because we crush all the sales targets. And that will not come to fruition by this September.

I still think we most likely see a BO offer Q1-2 next year, and hopefully we’re in a position of power/can say no to a $35-50 bid